CG Oncology, Inc.
cgoncology.comWhat Do They Do?
Develops an investigational treatment for patients with high- and intermediate-risk bladder cancer.
10-K for FY2025, filed Feb 27, 2026We are a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec…View ↗
How Do They Make Money?
CG Oncology earns revenue from manufacturing products supplied to customers and related development work. License and collaboration partners also pay upfront fees, development and commercial milestone payments when achieved, and royalties on product sales.
10-K for FY2025, filed Feb 27, 2026The Company’s performance obligations under the terms of these agreements include a license grant, research and development services or…View ↗
The License and Collaboration Agreements include milestone payments that are triggered by the achievement of development milestones. These…View ↗
The License and Collaboration Agreements also include certain sales-based milestone and royalty payments upon successful commercialization…View ↗
The Company recognizes revenue from the commercial and development contracts in accordance with ASC 606. Commercial and development revenue…View ↗
-
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗
$4M
-
10-K for FY2025, filed Feb 27, 2026
$4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Commercial and Development Revenue
|
80% |
Commercial and Development Revenue, FY2025
$3.2M Sources
|
|
|
License and Collaboration Revenue
Licensed
10-K for FY2025, filed Feb 27, 2026 |
20% |
License and Collaboration Revenue, FY2025
$806K Sources
|
Licensed |
Who Are Their Customers?
Kissei develops and commercializes the licensed product in its territory and buys its clinical and commercial supply from CG Oncology.
10-K for FY2025, filed Feb 27, 2026In March 2020, and as amended September 2022, we entered into a license and collaboration agreement (the Kissei Agreement) with Kissei…View ↗
Do Revenues Turn Into Profits?
No. It lost $161M in FY2025.
10-K for FY2025, filed Feb 27, 2026
−$190.8MView ↗
10-K for FY2025, filed Feb 27, 2026
−$161MView ↗
10-K for FY2025, filed Feb 27, 2026
−$132.4MView ↗
How Are They Changing?
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
-
Apr 13, 2026
Appointed Jim DeTore as chief financial officer
DeTore had served as interim principal financial and accounting officer since November 2025.
Sources
8-K, filed Apr 13, 2026
Mr. DeTore, age 61, has served as our Interim Principal Financial and Accounting Officer since November 2025 pursuant to a consulting…View ↗
Who Do They Compete With?
Competes with Bristol Meyers Squibb, enGene, Gilead Sciences, Roche, ImmunityBio, Johnson & Johnson, Merck, Protara Therapeutics, Pfizer, Relmada Therapeutics, and UroGen Pharma
10-K for FY2025, filed Feb 27, 2026We will continue to face competition from current standard of care treatments, including BCG. To the extent Merck or another manufacturer…View ↗
Loading...
